NCT00715182View on ClinicalTrials.gov

A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

87

Participants

Timeline

Start Date

July 31, 2008

Primary Completion Date

July 31, 2012

Study Completion Date

July 31, 2012

Conditions
Advanced/ Metastatic Renal Cell Cancer
Interventions
DRUG

TKI258

Trial Locations (12)

112

Novartis Investigative Site, Taipei

10002

Novartis Investigative Site, Taipei

27710

Novartis Investigative Site, Durham

28041

Novartis Investigative Site, Madrid

30625

Novartis Investigative Site, Hanover

33075

Novartis Investigative Site, Bordeaux

40705

Novartis Investigative Site, Taichung

81675

Novartis Investigative Site, München

94805

Novartis Investigative Site, Villejuif

Unknown

Novartis Investigative Site, San Francisco

98109-1023

Novartis Investigative Site, Seattle

3075 EA

Novartis Investigative Site, Rotterdam

Sponsors
All Listed Sponsors
lead

Novartis Pharmaceuticals

INDUSTRY